NAMI MD: New Medications in Development

Medication	Manufacturer	Indication	Status
U-101387	Pharmacia & Upjohn Kalamazoo, MI	schizophrenia	Phase II
citalopram	Forest Laboratories St. Louis, MO	depression	Phase III
flesinoxan	Solvay Marietta, GA	depression anxiety	Phase III
pregabalin	Parke-Davis Morris Plains, NJ	psychiatric disorders	Phase III
iloperidone	Novartis East Hanover, NJ	schizophrenia	Phase III
lamotrigine	GlaxoWellcome Research Triangle, NC	bipolar disorder	Phase III
M100907	Aventis Kansas City, MO	schizophrenia	Phase III
olanzapine	Eli Lilly Indianapolis, IN	bipolar disorder	application approved
ORG 5222	Organon West Orange, NJ	schizophrenia	Phase II
pagoclone	Interneuron Lexington, MA	anxiety	Phase II/III
reboxetine	Pharmacia & Upjohn Kalamazoo, MI	depression	application submitted
sunepitron	Pfizer, Inc. New York, NY	depression anxiety	Phase II
ziprasidone	Pfizer, Inc. New York, NY	schizophrenia	application submitted